Why is Bliss GVS Pharma falling/rising?

As of 14-Jul, Bliss GVS Pharma Ltd's stock is currently priced at 153.10, reflecting a decline of 0.9, or 0.58%. The stock has been experiencing a downward trend, having underperformed its sector by 1.48% today and showing a consecutive fall over the last five days, resulting in a total decline of 6.07%. Although the stock has generated a positive return of 32.21% over the past year, it has also seen a significant profit drop of 19.5%. The stock is trading at a premium compared to its peers, and while it has a low debt-to-equity ratio and an attractive valuation with a price-to-book value of 1.5, the recent performance indicates a struggle in maintaining investor interest, as evidenced by a 33.97% drop in delivery volume.
In the broader market context, the stock's short-term performance has been notably weaker than the benchmark, with a 1-week return of -6.07% compared to the Sensex's -1.42%. Despite the stock's long-term outperformance, including a 98.70% return over three years, the recent trend suggests that investors are cautious, particularly given the declining profits and reduced trading activity. The overall market has shown resilience with a 5.27% year-to-date return for the Sensex, contrasting with Bliss GVS Pharma's year-to-date decline of 7.01%. This disparity highlights the challenges the company faces in attracting and retaining investor confidence amidst broader market gains.